Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Oral Suspension of Merck's Isentress Approved | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Oral Suspension of Merck’s Isentress Approved

Formulation cleared to treat HIV in patients four weeks old

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The FDA has approved Isentress for oral suspension, a pediatric formulation of Merck’s integrase inhibitor. The approval opens up Isentress, in combination with other antiretroviral (ARV) agents, for the treatment of HIV-1 infection in patients four weeks of age and older. The use of other active agents with Isentress is associated with a greater likelihood of treatment response, according to Merck.

The oral suspension may be used in patients as young as four weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of Isentress have not been established in infants less than four weeks of age. Formulations of Isentress for specific populations now include oral suspension, chewable tablets and film-coated tablets. The oral suspension formulation of Isentress will be available in the U.S. during 3Q14.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics